drugset
drugset / Trial / NCT05779163

A Phase I/II Clinical Trial of LBL-033 in the Treatment of Advanced Malignant Tumors

NCT05779163 ↗

Phase 1/2 Completed 26 enrolled Nanjing Leads Biolabs Co.,Ltd
NaSingle-groupOpen-labelTreatment

Summary

This trial is an open and multicenter phase I/II clinical study, which aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and effectiveness.

Timeline

Start
2023-04-14
Primary completion
2025-04-03
Completion
2025-04-03

Drugs

EvaluationDrugModalityDoseRoute
Subject LBL-033 Unknown — Intravenous

Indications

cancer